CN1275610C - Plant extract composition for preventing and treating myopia and sight fatigne and its preparation method - Google Patents
Plant extract composition for preventing and treating myopia and sight fatigne and its preparation method Download PDFInfo
- Publication number
- CN1275610C CN1275610C CN 01130184 CN01130184A CN1275610C CN 1275610 C CN1275610 C CN 1275610C CN 01130184 CN01130184 CN 01130184 CN 01130184 A CN01130184 A CN 01130184A CN 1275610 C CN1275610 C CN 1275610C
- Authority
- CN
- China
- Prior art keywords
- bilberry
- starch
- extract
- eye
- myopia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a plant extract composition for preventing and curing myopia and asthenopia. The present invention is characterized in that the composition is prepared from bilberry fruit extract, ginkgo leaf extract and starch, wherein the raw material components have the weight percent of 10 to 99% of bilberry fruit extract, 1 to 90% of ginkgo leaf extract and 0 to 50% of starch. The present invention uses the biologic extraction process: a, bilberry fruit is pulverized and boiled with water at the temperature of 45 to 80 DEGC to remove pectin, ethanol is added to remove the starch, and then, the bilberry fruit is concentrated to manufacture bilberry fruit extract powder; b, ginkgo leaves are heated twice and extracted, ethanol is added for extraction, and ethanol solution with the ginkgo leaf extract is recovered and then concentrated to manufacture ginkgo leaf extract powder; c, the raw materials are proportioned, mixed and separately packed according to the raw material components. The present invention is manufactured by that an advanced biologic extraction process is used for extracting effective components of the bilberry fruit and the ginkgo leaves. The present invention combines safety, high performance and convenience into a whole and has the effects on preventing and curing asthenopia and myopia, protecting eyes and increasing vision.
Description
Technical field
The present invention relates to medicine biological technique, specifically is a kind of control myopia and asthenopic composition of plant extracts and preparation method thereof.
Background technology
Show that according to relevant investigation statistics data China's myopia disease patient number has reached 4.3 hundred million, accounts for 33.6% of China's total population, and present the trend of " overall radix is increasing, and the initial patient age is more and more littler ".Wherein, the adolescent myopia problem becomes the focus that the whole society pays close attention to especially.According to statistics, have 63.77% people to suffer from various degree myopia among the students in middle and primary schools of cities and towns, because myopia, a lot of students have just put on heavy glasses at the slight age, not only influence attractive in appearance, studying and living, have more restricted the development of individual speciality and hobby.
Along with science and technology development, popularizing of computer, people are more and more higher with the frequency of eye, teacher, student, computer operator, driver, deskman, night job personnel and writer, editor, accounting, designer or the like, because frequent excess eye-using, dried, the asthenopia symptoms such as eye is puckery, eye acid, ophthalmic bloated, ophthalmalgia, dim eyesight even black eye, dizziness, headache, nauseating, insomnia and visual deterioration that often go out to lose face have a strong impact on study, life and healthy.1999 and the continuous statistics in 2 years demonstration in 2000, because of the patient that asthenopia causes hypometropia or myopic degree to be deepened, just the speed with every year 23% increases.
Present lack relative of control product with means at the myopia disease, mainly contain operation, eye drop, picture frame glasses, contact lens, external eye care instrument etc., though certain effect is arranged, but all there are many defectives separately, still lack the control myopia and the asthenopic medicine that really integrate " safety, effective, convenient " on the market.
Summary of the invention
The object of the present invention is to provide a kind of control myopia and asthenopic composition of plant extracts, and the preparation method of said composition.
Composition of plant extracts of the present invention comprises: bilberry extract, Folium Ginkgo extract and starch, wherein the weight percent content of each material component is, bilberry extract 10-99%, Folium Ginkgo extract 1-90%, starch 0-50%.
A kind of preparation method of preventing and treating myopia and asthenopic composition of plant extracts is characterized in that taking following steps:
A, will clean back bilberry fragmentation, decocting in water under 45-80 ℃ of temperature is removed pectin, adds 3 times of amount ethanol and removes starch, concentrates then and makes bilberry extract dry powder;
B, the heating of the Folium Ginkgo after will cleaning second extraction add the ethanol extraction of 5 times of amounts, reclaim the alcoholic solution that contains the Folium Ginkgo extract, concentrate then and make Folium Ginkgo extract dry powder;
C, according to its material component batching, mix, packing, wherein each material component content is: bilberry extract 10-99%, Folium Ginkgo extract 1-90%, starch 0-50%.
The effective ingredient that combination system of the present invention adopts advanced biological extraction technology to extract bilberry and Folium Ginkgo is made, and Jian is complete, efficient, be convenient to one, has control asthenopia and myopia, and the protection eyes improve the effect of vision.Be applicable to the adolescent student of myopia, pseudomyopia and the crowd of visual deterioration, can effectively prevent the generation and the development of myopia; Be applicable to with eye work serve as mainly cause that eye is done, eye is puckery, the old and young of asthenopia symptoms such as eye acid, ophthalmic bloated, ophthalmalgia, dim eyesight, black eye, dizziness, headache, nauseating, insomnia and visual deterioration, can effectively prevent and the alleviating asthenopia symptom; This product also is applicable to glaucoma and the myopia that diabetes cause, the function of energy microcirculation improvement, the secretion that increases erythropsin, adjusting ciliary muscle.Have originality, wide practical value is arranged.
The precious oral capsule of eye of the present invention is as follows through clinical test results: but the health-care capsule obvious and effective of eye is improved the visual fatigue symptom, alleviates the discomfort that eye and whole body bring because of eyesight overuses; The person's that can significantly improve the adolescent myopia vision, to pseudomyopia, low myopia and nongenetic myopia treatment improvement effect arranged in early days, the generation development of myopia is had preventive effect.
Description of drawings
Fig. 1 is preparation technology's flow chart of composition of plant extracts of the present invention.
The specific embodiment
Below in conjunction with embodiment the present invention is advanced a description.
Said composition is made by bilberry extract, Folium Ginkgo extract and starch, and wherein the weight percent content of each material component is, bilberry extracts 70%, Folium Ginkgo extract 20%, starch 10%.
The preparation technology of composition of plant extracts of the present invention as shown in Figure 1.Prepare bilberry extract, Folium Ginkgo extract dry powder respectively, select starch material, then by its material component batching.Its typical process is as follows: a, will clean back bilberry fragmentation, decocting in water is 30 minutes under 60 ℃ of temperature, removes pectin, adds 3 times of amount ethanol and removes starch, concentrates then and makes bilberry extract dry powder; B, the heating of the Folium Ginkgo after will cleaning second extraction add the ethanol extraction of 5 times of amounts, reclaim the alcoholic solution that contains the Folium Ginkgo extract, concentrate then and make Folium Ginkgo extract dry powder; C, get bilberry extract dry powder 70%, Folium Ginkgo extract dry powder 20% and starch 10% and fully mix, packing such as capsule are finished product.
According to different instructions for uses, the content of the each component of composition of plant extracts of the present invention can be bilberry extract 25%, Folium Ginkgo extract 70%, starch 5%; Or bilberry extract 80%, Folium Ginkgo extract 20%.Its preparation technology is described with the above embodiments, repeats no more.
This control myopia and asthenopic plant are mentioned compositions and can make powder, as the precious oral capsule of eye.Also can make tablet, oral liquid etc.
The active ingredient of this product is bilberry extract and Folium Ginkgo extract.Cranberry extract is one of Main Ingredients and Appearance of this product, and Pericarpium Citri tangerinae has another name called Fructus Vaccinii Bracteati, is natural wild evergreen shrubs, originates in Europe, and the bilberry diameter is about 1cm, spherical shape, skin blueness, is commonly called as blue berry.The history that more than 100 year edible this fruit arranged among the people in Northern Europe, this fruit of finding in the process of eating among the people has the effect of adjusting eye fatigue, and can improve nyctalopia, pre-myopia prevention, presbyopia, glaucoma.Europe and Japan developed research to this kind of plant in recent years, extracted its elite and active ingredient, made the protection eyes, improved the health food of vision.Through the research of how tame research department, evidence, this really mainly contains effective constituent is anthocyanin.Anthocyanin has the generation of regulating blood flow, microcirculation improvement, promotion erythropsin, the function of improving ciliary muscle, and then guarantees the refractive index of lens, prevents the generation and the development of myopia.
Folium Ginkgo extract is another Main Ingredients and Appearance of this product, the function of Folium Ginkgo mainly is to eliminate intravital free radical, microcirculation improvement, safeguard vascular permeability, promote the blood circulation of brain and the metabolism of brain cell, improve the hypoxia-bearing capability of brain, two kind of plant are mixed, can strengthen the regulatory function of anthocyanidin to eye, play coordinative role, this scientific combination has brought very ideal effect for this product.
Be subjected to health ministry food supervision and inspection trust, Shenzhen City Second People's Hospital ophthalmology has been presided over the clinical trial of " health-care capsule of extra large trump eye ", test situation is as follows:
(1) material and method
1, study subject
From calendar year 2001 JIUYUE 21 days between October 26 calendar year 2001,171 teenager of picked at random Shenzhen voluntary participation have carried out clinical trial, to being divided into treatment group and matched group, the treatment group is to take " health-care capsule of extra large trump eye " (0.33 gram/grain) secondary every day, each one, one month course of treatment; Matched group is taken placebo (0.33 gram/grain) secondary every day that starch is made, each one.The full person of eliminating data, totally 126 of the persons that finally chooses all information, wherein male 56 people, women 70 people, the age was between 10-25 year, average 15 years old.Matched group 54 people, wherein male 28 people, women 26 people, the age was between 10-25 year, average 15.9 years old; 72 people are organized in treatment, wherein male 28 people, and women 44 people, the age was between 10-25 year, average 14.3 years old.
2, method of administration
The treatment group: oral " health-care capsule of eye " one time one (0.33 gram/grain), every day secondary.
Matched group: one of oral placebo (starch) capsule one time, secondary every day (0.33 gram/grain, composition are starch), no any difference on placebo and " health-care capsule of eye " profile.
Each experimenter is only carried out the function introduction of simple eye care knowledge and product, and all experimenters do not know in the product of taking contains placebo, and whole process is carried out under the situation of " double blinding ".
3, detection method
All study subjects carry out ophthalmologic examinationes such as vision logarithmic visual acuity chart, slit lamp, ophthalmofundoscope, quick mydriasis computerized optometry before taking, routine blood test, routine urianlysis have also carried out inspections such as hepatic and renal function, B ultrasonic, electrocardiogram more than 20 years old.
After taking the end course of treatment, this study subject is carried out ophthalmologic examinationes such as vision, slit lamp, ophthalmofundoscope, quick mydriasis computerized optometry, routine blood test, routine urinalysis, liver, kidney function test.
Before and after all experimenters take, respectively eye symptom is registered, eye visual fatigue symptom with do not have (0 minute), light (1 minute), in (2 minutes), heavy (3 minutes) classification, and add up with integrated value.
4, criterion
1) symptom
Improve: before 1. taking integration is arranged, taking the back integration is zero person;
2. integration is all arranged before and after taking, but integration deducts and takes back integration 〉=1 before taking.
Invalid: as 1. to take the back and take foreset and divide identical person;
2. take the back integration greater than integration person before taking;
3. take foreset and be divided into zero, take back integration 〉=1.
2) vision
Improve (raising): the logarithmic visual acuity chart inspection, take the back vision and take preceding vision raising two row above (comprising two row).
Invalid: 1. logarithmic visual acuity chart inspection, the vision raising was less than two row before vision was taken after taking;
2. vision attenuating person before taking after taking;
3) diopter
Improve: computerized optometry behind the mydriasis fast was as the criterion with (comprising 0.5D) more than reducing 0.5D before taking after taking.
5, result's statistics
Symptom: doing well,improving is added up with integration method before and after taking, two groups of sample averages relatively with t check, doing well,improving rate X
2Check.
Vision: vision is added up with logarithmic visual acuity chart 5 minutes system before and after taking, two groups of sample averages relatively with t check, eyesight improving rate X
2Check.
Diopter: diopter before and after taking, relatively the checking of two groups of means with t.
Routine blood test (WBC, RBC, HGB), and before and after taking, relatively the checking of two groups of means with t.
(2) result
The X of 1, treatment group and matched group doing well,improving rate
2Check (spss 8.0 editions) sees Table 3.
2, treatment group and matched group eyesight improving rate X
2Check sees Table 4.
3, treatment group symptom integral method, t check before and after taking, P＜0.005, significant difference illustrates that taking the backsight fatigue symptom improves obviously.
4, treatment group vision: take back vision mean and improve greater than two row, t checks P＜0.005, and significant difference illustrates that taking back vision raising has the significance meaning.
5, t check before and after treatment group diopter is taken, p＞0.05 is so think and take the no significance difference in front and back.
(3) clinical evaluation
Compare with matched group, oral " health-care capsule of eye " after January, and eye asthenopia symptom (comprise that ophthalmalgia, ophthalmic bloated, photophobia, eye are dry and astringent, blurred vision, eye fatigue etc.) is obviously improved.Taking the back integration is 1.21, and integration 4.18 reduces obviously before taking.The improvement rate is up to 94.12%, and (and the improvement rate of matched group is 13.21%) learned by statistics and handled (X
2Check), P＜0.005, significant difference.Most of experimenters take " treasured of eye " aftersensation " limpid many " " eye is light a lot " at the moment.
Logarithmic visual acuity chart is that vision improves standard improving two row above (comprising two row) with vision under the standard light illumination, find in this research, take " treasured of eye " capsule after one month, there is 82.71% experimenter's eye vision to improve two row or more than two row, and matched group only is to compare (X between 1.94%, two group
2Check), P＜0.005, so the treatment group improves obviously than the matched group vision, promptly " treasured of eye " can obviously improve teen-age vision.
By observing, find that " treasured of eye " is less to dioptric influence, learn by statistics and handle, P＞0.05, take the front and back difference and do not have significance, possible reason: this may be that the lengthening of sagittal diameter is relevant with the front and back diameter of patient's eyeball.
Find to take the content (the front and back every content's index of twice detection is all in normal range) that " health-care capsule of eye " can improve body circulation and leukocyte, erythrocyte and haemachrome in this research.(t check) by statistics, P＜0.05, difference slightly, this mainly is the cause that contains the auxiliary element Folium Ginkgo in the prescription of " health-care capsule of eye ".Now gain public acceptance, Folium Ginkgo is to microcirculation improvement, and improving human body oxytolerant power has remarkable result.The latter reaches by amount and the oxygen carrying capacity that improves RBC and HGB.
Any toxic and side effects Sx do not occur after finding in this research to take " treasured of eye " capsule, do not find that it has any harmful effect to system's organ.
(4) conclusion
" health-care capsule of eye " but significant effective ground improves the visual fatigue symptom, alleviate the discomfort that eye and whole body bring because of eyesight overuses.
" health-care capsule of the eye " person's that can significantly improve the adolescent myopia vision has a treatment improvement effect in early days to pseudomyopia, low myopia and nongenetic myopia.Generation development to myopia has preventive effect.
" treasured of eye " is one to have a high potential, and outstanding effect is improved vision and alleviated asthenopic health food.
Do not find " treasured of eye " any toxic and side effects to human body.
The X of treatment group and matched group doing well,improving rate
2Check (table 1)
Treatment group and matched group eyesight improving rate X
2Check (table 2)
Claims (2)
1, a kind of preparation method of preventing and treating myopia and asthenopic composition of plant extracts is characterized in that taking following steps:
A, will clean back bilberry fragmentation, decocting in water under 45-80 ℃ of temperature is removed pectin, adds 3 times of amount ethanol and removes starch, concentrates then and makes bilberry extract dry powder;
B, the heating of the Folium Ginkgo after will cleaning second extraction add the ethanol extraction of 5 times of amounts, reclaim the alcoholic solution that contains the Folium Ginkgo extract, concentrate then and make Folium Ginkgo extract dry powder;
C, according to its material component batching, mix, packing, wherein each material component content is: bilberry extract dry powder 10-99%, Folium Ginkgo extract dry powder 1-90%, starch 0-50%.
2, the preparation method of composition of plant extracts according to claim 1 is characterized in that: in step a, with the bilberry of fragmentation decocting in water 30 minutes under 60 ℃ of temperature.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01130184 CN1275610C (en) | 2001-12-30 | 2001-12-30 | Plant extract composition for preventing and treating myopia and sight fatigne and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01130184 CN1275610C (en) | 2001-12-30 | 2001-12-30 | Plant extract composition for preventing and treating myopia and sight fatigne and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1429563A CN1429563A (en) | 2003-07-16 |
| CN1275610C true CN1275610C (en) | 2006-09-20 |
Family
ID=4669808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01130184 Expired - Fee Related CN1275610C (en) | 2001-12-30 | 2001-12-30 | Plant extract composition for preventing and treating myopia and sight fatigne and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1275610C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018212152A1 (en) * | 2017-05-15 | 2018-11-22 | 株式会社坪田ラボ | Composition and functional food for preventing myopia |
| JP2018193357A (en) * | 2017-10-31 | 2018-12-06 | 株式会社坪田ラボ | Composition for preventing myopia, and functional food |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387154C (en) * | 2005-11-25 | 2008-05-14 | 南京中科集团有限公司 | Health-care food for relieving-vision fatigue and its prepn. method |
| CN101850028B (en) * | 2009-10-16 | 2011-08-17 | 北京同仁堂健康药业股份有限公司 | Composition with function of relieving visual fatigue |
| CN101972026A (en) * | 2010-09-21 | 2011-02-16 | 湖南凯勒迪化学科技有限公司 | Vaccinium bracteatum health product and preparation method thereof |
| CN103087826A (en) * | 2011-11-08 | 2013-05-08 | 江西中烟工业有限责任公司 | Blueberry extract and preparation method thereof and application in cigarette |
| CN109090611B (en) * | 2018-10-26 | 2022-01-07 | 汤臣倍健股份有限公司 | AGEs inhibition composition, application, preparation method and preparation thereof |
-
2001
- 2001-12-30 CN CN 01130184 patent/CN1275610C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018212152A1 (en) * | 2017-05-15 | 2018-11-22 | 株式会社坪田ラボ | Composition and functional food for preventing myopia |
| TWI787268B (en) * | 2017-05-15 | 2022-12-21 | 日商坪田實驗室股份有限公司 | Composition and functional food for preventing myopia |
| US11813299B2 (en) | 2017-05-15 | 2023-11-14 | Tsubota Laboratory, Inc. | Composition and functional food for preventing myopia |
| JP2018193357A (en) * | 2017-10-31 | 2018-12-06 | 株式会社坪田ラボ | Composition for preventing myopia, and functional food |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1429563A (en) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1943693A (en) | Traditional Chinese medicine preparation for eye health care and asthenopia alleviation | |
| CN1275610C (en) | Plant extract composition for preventing and treating myopia and sight fatigne and its preparation method | |
| CN1178682A (en) | Chinese drug Mingmudan pill for improving eyesight and its producing method | |
| CN105106286A (en) | Health product with effects of protecting eyes and improving eyesight | |
| CN1973873A (en) | Eye health food capsule | |
| CN1255178C (en) | Externally used traditional Chinese medicine preparation for treating teenager myopia and its preparing method | |
| CN104147380B (en) | It is a kind of that there is the pharmaceutical composition for alleviating visual fatigue effect, preparation method and application | |
| CN114010591B (en) | External traditional Chinese medicine gel ointment for treating asthenopia and preparation method thereof | |
| CN115645454A (en) | External cream for treating myopia and preparation method thereof | |
| CN1478533A (en) | Chinese Medicine for treating cervieal vertebra disease and its preparation method | |
| CN107029037A (en) | It is a kind of to improve the eyesight-improving health care function patch of eyes based on nitric oxide principle | |
| CN103816286A (en) | Vaccinium spp. compound oral solution formula for alleviating asthenopia, and preparation technique thereof | |
| RU2512801C1 (en) | Therapeutic eye balsam | |
| CN103251725B (en) | A kind of application of Chinese medicine composition in treatment keratitis medicine is prepared | |
| CN112451622A (en) | A preparation for treating myopia, amblyopia and astigmatism, and its preparation method | |
| CN108498615A (en) | A kind of Chinese herb medicine eye health-care patch and preparation method thereof improving eyes based on nitric oxide principle | |
| CN111820413A (en) | Lutein blueberry grape seed vitamin E soft capsule and preparation method thereof | |
| CN1123350C (en) | Chinese patent medicine (Tangweiping) for treating eyeground affection of diabetes | |
| CN116211984B (en) | A Chinese medicinal composition eye ointment for preventing and treating myopia of children and teenagers, and its preparation method | |
| CN103751358B (en) | A kind of Chinese medicine composition for rescuing ametropia ophthalmic | |
| CN108991364A (en) | A kind of black pine novel foodstuff and preparation method thereof | |
| CN101856429A (en) | Medicine compound with visual fatigue relieving function and preparation method thereof | |
| CN1073600A (en) | The preparation method of the Chinese medicine preparation of treatment pseudomyopia | |
| CN1238213A (en) | Medicinal capsules for improving vision and its preparing method | |
| CN118319977A (en) | Eyedrops and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |